In September 2025, the FDA issued more than 50 warning letters to companies compounding or marketing GLP-1 products including semaglutide, tirzepatide, and retatrutide
in particular, the treatment with empagliflozin in the EMPA-REG OUTCOME study (T2D patients who were at high risk of cardiovascular disease) showed no significant between-group differences in the rates of myocardial infarction or stroke, although in the empagliflozin group, significantly lower rates of death from cardiovascular causes (3.7% vs
Appetite changes, dose decisions, and anything that worries you belong with your doctor or licensed clinician
Scientific Reference 2: Wilding et al., New England Journal of Medicine (2021) 2
Monitoring Your Progress With Ozempic Keeping track of how much weight you are losing is very crucial